To include your compound in the COVID-19 Resource Center, submit it here.

Telaprevir: Additional Phase III data

A retrospective analysis of 527 patients from the double-blind, international Phase III REALIZE trial in 662 patients with HCV genotype 1 infection who failed previous therapy showed that telaprevir plus standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus ribavirin) produced SVR rates, defined as undetectable

Read the full 462 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE